{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:44:39Z","timestamp":1792176279623,"version":"4.4.0"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["NNF20OC0060657"],"award-info":[{"award-number":["NNF20OC0060657"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Use of inhaled corticosteroids (ICS) is common in patients with chronic obstructive pulmonary disease (COPD) and has been associated with an increased risk of pneumonia.<jats:italic>Moraxella catarrhalis<\/jats:italic>is one of the most common bacterial causes of infectious exacerbation in COPD. Currently, to our knowledge, no studies have investigated if ICS increases the risk of lower respiratory tract infection with<jats:italic>M. catarrhalis<\/jats:italic>in patients with COPD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate if accumulated ICS use in patients with COPD, is associated with a dose-dependent risk of infection with<jats:italic>M. catarrhalis<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational cohort study included 18\u2009870 persons with COPD who were registered in The Danish Register of COPD. Linkage to several nationwide registries was performed.<\/jats:p><jats:p>Exposure to ICS was determined by identifying all prescriptions for ICS, redeemed within 365 days prior to study entry. Main outcome was a lower respiratory tract sample positive for<jats:italic>M. catarrhalis<\/jats:italic>. For the main analysis, a Cox multivariate regression model was used.<\/jats:p><jats:p>We defined clinical infection as admission to hospital and\/or a redeemed prescription for a relevant antibiotic, within 7 days prior to 14 days after the sample was obtained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found an increased, dose-dependent, risk of a lower respiratory tract sample with<jats:italic>M. catarrhalis<\/jats:italic>among patients who used ICS, compared with non-users. For low and moderate doses of ICS HR was 1.65 (95% CI 1.19 to 2.30, p=0.003) and 1.82 (95% CI 1.32 to 2.51, p=0.0002), respectively. In the group of patients with highest ICS exposure, the HR of<jats:italic>M. catarrhalis<\/jats:italic>was 2.80 (95% CI 2.06 to 3.82, p&lt;0.0001). Results remained stable in sensitivity analyses. 87% of patients fulfilled the criteria for clinical infection, and results remained unchanged in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study shows a dose-dependent increased risk of infection with<jats:italic>M. catarrhalis<\/jats:italic>associated to ICS exposure.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjresp-2023-001726","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T12:10:35Z","timestamp":1692447035000},"page":"e001726","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Inhaled corticosteroids and risk of lower respiratory tract infection with<i>Moraxella catarrhalis<\/i>in patients with chronic obstructive pulmonary disease"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1112-0820","authenticated-orcid":false,"given":"Rikke Helin","family":"Johnsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-3235","authenticated-orcid":false,"given":"Christian Kjer","family":"Heerfordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Bredtoft","family":"Boel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1497-6309","authenticated-orcid":false,"given":"Ram Benny","family":"Dessau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ostergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeesh","family":"Sivapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Ekl\u00f6f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Ulrik St\u00e6hr","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"2023081905100962000_10.1.e001726.1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2023."},{"key":"2023081905100962000_10.1.e001726.2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2023081905100962000_10.1.e001726.3","doi-asserted-by":"crossref","unstructured":"Nannini LJ , Poole P , Milan SJ , et al . Combined corticosteroid and long-acting Beta(2)-Agonist in one Inhaler versus long-acting Beta(2)-Agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;2013:CD003794. doi:10.1002\/14651858.CD003794.pub4","DOI":"10.1002\/14651858.CD006829.pub2"},{"key":"2023081905100962000_10.1.e001726.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"2023081905100962000_10.1.e001726.5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of Budesonide\/glycopyrrolate\/Formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2023081905100962000_10.1.e001726.6","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with Fluticasone Furoate\/Umeclidinium\/Vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2023081905100962000_10.1.e001726.7","doi-asserted-by":"crossref","unstructured":"Kew KM , Seniukovich A , Cochrane Airways Group . n.d. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev;2014. doi:10.1002\/14651858.CD010115.pub2","DOI":"10.1002\/14651858.CD010115.pub2"},{"key":"2023081905100962000_10.1.e001726.8","doi-asserted-by":"crossref","unstructured":"Yang IA , Clarke MS , Sim EHA , et al . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;2012:CD002991. doi:10.1002\/14651858.CD002991.pub3","DOI":"10.1002\/14651858.CD002991.pub3"},{"key":"2023081905100962000_10.1.e001726.9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/biomedicines9101312","article-title":"Inhaled corticosteroids and the lung Microbiome in COPD","volume":"9","author":"Keir","year":"2021","journal-title":"Biomedicines"},{"key":"2023081905100962000_10.1.e001726.10","doi-asserted-by":"crossref","unstructured":"Contoli M , Pauletti A , Rossi MR , et al . Long-term effects of inhaled corticosteroids on Sputum bacterial and viral loads in COPD. Eur Respir J 2017;50:1700451. doi:10.1183\/13993003.00451-2017","DOI":"10.1183\/13993003.00451-2017"},{"key":"2023081905100962000_10.1.e001726.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2013.09.012"},{"key":"2023081905100962000_10.1.e001726.12","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.1.125-144.2002"},{"key":"2023081905100962000_10.1.e001726.13","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1016\/j.vaccine.2016.12.066","article-title":"Potential impact of a Moraxella catarrhalis vaccine in COPD","volume":"37","author":"Perez","year":"2019","journal-title":"Vaccine"},{"key":"2023081905100962000_10.1.e001726.14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/23744235.2022.2092648","article-title":"Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study","volume":"54","author":"Malvisi","year":"2022","journal-title":"Infect Dis (Lond)"},{"key":"2023081905100962000_10.1.e001726.15","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201310-350OC"},{"key":"2023081905100962000_10.1.e001726.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200412-1747OC"},{"key":"2023081905100962000_10.1.e001726.17","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S99489"},{"key":"2023081905100962000_10.1.e001726.18","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811401482"},{"key":"2023081905100962000_10.1.e001726.19"},{"key":"2023081905100962000_10.1.e001726.20","unstructured":"European Medicines Agency . Type II variation assessment report for Relvar and Revinty Ellipta; 2015, EMA\/499766\/2015."},{"key":"2023081905100962000_10.1.e001726.21","unstructured":"Inhaled corticosteroid doses for NICE\u2019s asthma guideline. National Institute for Health and Care Excellence 2018."},{"key":"2023081905100962000_10.1.e001726.22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5753"},{"key":"2023081905100962000_10.1.e001726.23","unstructured":"Cefalu M , Ridgeway G , McCaffrey D , et al . Toolkit for weighting and analysis of nonequivalent groups, R package (version 2.5.2021)."},{"key":"2023081905100962000_10.1.e001726.24","doi-asserted-by":"crossref","unstructured":"Koarai A , Yamada M , Ichikawa T , et al . Triple versus LAMA\/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. Respir Res 2021;22:183. doi:10.1186\/s12931-021-01777-x","DOI":"10.1186\/s12931-021-01777-x"},{"key":"2023081905100962000_10.1.e001726.25","doi-asserted-by":"crossref","unstructured":"Miravitlles M , Auladell-Rispau A , Monteagudo M , et al . Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev 2021;30:210075. doi:10.1183\/16000617.0075-2021","DOI":"10.1183\/16000617.0075-2021"},{"key":"2023081905100962000_10.1.e001726.26","doi-asserted-by":"crossref","unstructured":"Sim YS , Lee JH , Lee EG , et al . COPD exacerbation-related pathogens and previous COPD treatment. J Clin Med 2022;12:111. doi:10.3390\/jcm12010111","DOI":"10.3390\/jcm12010111"},{"key":"2023081905100962000_10.1.e001726.27","doi-asserted-by":"crossref","unstructured":"Ekl\u00f6f J , Ingebrigtsen TS , S\u00f8rensen R , et al . Use of inhaled corticosteroids and risk of acquiring. Thorax 2021. doi:10.1136\/thoraxjnl-2021-217160","DOI":"10.1136\/thoraxjnl-2021-217160"},{"key":"2023081905100962000_10.1.e001726.28","doi-asserted-by":"crossref","unstructured":"Mohsin RU , Heerfordt CK , Ekl\u00f6f J , et al . Use of inhaled corticosteroids and risk of acquiring Haemophilus Influenzae in patients with chronic obstructive pulmonary disease. J Clin Med 2022;11:3539. doi:10.3390\/jcm11123539","DOI":"10.3390\/jcm11123539"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-001726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T12:10:47Z","timestamp":1692447047000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-001726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,18]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bmjresp-2023-001726"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-001726","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}